サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1774834

女性性機能障害治療の世界市場

Female Sexual Dysfunction Treatment

出版日
ページ情報
英文 478 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.79円
女性性機能障害治療の世界市場
出版日: 2025年07月23日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 478 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

女性性機能障害治療の世界市場は2030年までに8億5,380万米ドルに達する見込み

2024年に5億2,860万米ドルと推定される女性性機能障害治療の世界市場は、2030年には8億5,380万米ドルに達し、分析期間2024-2030年のCAGRは8.3%で成長すると予測されます。本レポートで分析したセグメントの1つであるフリバンセリンは、CAGR 8.6%を記録し、分析期間終了時には3億4,240万米ドルに達すると予想されます。ブレメラノチドセグメントの成長率は、分析期間中CAGR 5.7％と推定されます。

米国市場は1億4,400万米ドルと推定、中国はCAGR13.0％で成長すると予測

米国の女性性機能障害治療市場は、2024年に1億4,400万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを13.0%として、2030年までに1億8,460万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.2%と8.0%と予測されています。欧州では、ドイツがCAGR 5.5%で成長すると予測されています。

世界の女性性機能障害治療市場- 主要動向と促進要因まとめ

女性性機能障害がようやく臨床的・商業的に注目されるようになったのはなぜか？

数十年にわたる限定的な認識の後、女性性機能障害（FSD）は現在、重大かつ多面的な健康問題として認知され、臨床上の注目と市場開拓に拍車をかけています。FSDは、性欲減退（低活動性性欲障害）、興奮障害、オーガズム機能障害、および性交困難症のような痛みに関連する症状など、さまざまな症状を含みます。社会的タブー、偏見、医学的トレーニングの不足のために、歴史的に過小診断されてきたこの疾患は、女性の全体的な健康と幸福を構成する正当な要素として見なされるようになってきています。この変化の一因は、文化的態度の変化、健康擁護における女性の声の高まり、そしてリプロダクティブ・ヘルスにとどまらないセクシュアル・ウェルネス・ソリューションに対する需要の高まりにあります。これを受けて、ヘルスケアプロバイダーや製薬会社は、男性の性機能障害に適用されるのと同じ科学的厳密さでFSDにアプローチし始めています。これには、具体的な診断基準の開発、フリバンセリンやブレメラノチドのようなFDA承認の治療法、FSDの根底にあるホルモン、神経、心理、および人間関係の要因を理解するための臨床研究の発展が含まれます。

医薬品および非医薬品の革新は、治療の展望をどのように変えているのか？

FSDの治療の展望は、ホルモン療法にとどまらず、医薬品や非医薬品による幅広い選択肢へと広がりつつあります。エストロゲン補充やアンドロゲン療法などの伝統的な治療法は、現在、セロトニンとドーパミンの経路を標的として性欲を増強するフリバンセリンのような中枢作用薬によって補完されています。メラノコルチン受容体作動薬であるブレメラノチドは、閉経前女性にオンデマンド療法を提供するもうひとつの画期的な薬物です。これらと並行して、研究者たちはオキシトシンアナログや選択的エストロゲン受容体モジュレーターを含む新しい薬剤クラス別を探求しており、いくつかの薬剤は様々な臨床試験段階にあります。非薬理学的アプローチもまた、特にホリスティックな、あるいは非侵襲的な選択肢を求める女性の間で支持を集めています。これには、認知行動療法、マインドフルネスに基づく介入、骨盤底理学療法、膣レーザーや神経調節ツールのようなハイテク機器の使用などが含まれます。遠隔医療プラットフォームとデジタル治療法は、特に十分なサービスを受けられない、あるいは保守的な環境にいる女性にとって、治療をより身近で、慎重で、カスタマイズ可能なものにしています。セクシュアル・ウェルネスがより広範な女性の健康アプリに統合されることで、FSDはさらに非対称化され、症状の追跡、行動修正、バーチャルカウンセリングが容易になります。

どのような文化的、心理的、人口統計学的な変化が治療の普及を促しているのか？

文化的な物語、心理学的な認識、人口統計学的なパターンの変化が、FSD治療に対するより高い需要を牽引しています。女性のセクシュアリティをめぐる社会的受容と教育が広まったおかげで、今日の女性は、自分の性的幸福を優先し、ヘルスケア提供者とオープンにコミュニケーションをとる力をより強く与えられています。特にミレニアル世代とZ世代は、セクシュアル・ヘルスをタブー視するのではなく、QOL（生活の質）の問題として再定義するのに役立っており、また、これまで見過ごされがちであった閉経後の女性は、加齢に伴う性欲や快適さの変化に対処する解決策を求めています。さらに、メンタルヘルスと性機能との関連性に対する認識が高まり、不安、身体イメージ、人間関係の力学などの心理的要因が診断や治療のプロセスの一部となっています。これと並行して、ウェルネス文化、ボディ・ポジティブ、セックス・ポジティブ・フェミニズムの人気が、性的充足をサポートする製品やサービスに対する消費者主導の需要を後押ししています。その結果、女性は臨床治療とライフスタイルを向上させるサプリメントの両方を、専門クリニック、オンライン・プラットフォーム、小売ウェルネス・ブランドに求めるようになっています。このような意識の変化は、より受容的な市場環境を作り出し、患者と医療提供者の間でよりしっかりとした話し合いが行われることを促しています。

世界市場の成長を加速させる業界勢力と臨床ニーズとは？

女性性機能障害治療市場の成長は、医療の進歩、消費者の嗜好の変化、ヘルスケア提供システムの進化に根ざしたいくつかの要因によって牽引されています。中でも重要なのは、セクシュアル・ウェルネスのために医療介入を求める女性の増加であり、これは女性中心のヘルスケア・サービスに対する認識、教育、アクセシビリティの向上に支えられています。企業プロファイルは、複数のFSDサブタイプやホルモンプロファイルに対応する薬剤のパイプラインを増やしながら、標的治療の研究開発に積極的に投資しています。遠隔医療や消費者直販プラットフォームの拡大により、特に性の健康に関する直接の話し合いがタブー視されている市場において、秘密厳守の相談や処方サービスへのアクセスが劇的に改善されています。先進諸国におけるヘルスケア支出の増加と保険適用範囲の拡大も、より多くの女性が伝統的な治療法と新たな治療法の両方を検討することを可能にしています。加えて、世界の女性人口の高齢化（特に平均余命の長い地域）は、閉経後のセクシュアル・ヘルス・ソリューションに対する持続的な需要を生み出しています。婦人科医、内分泌専門医、精神衛生専門家、セクシュアル・ヘルス専門家の間のセクターを超えた協力関係は、FSDの複雑な性質によりよく対処する学際的ケアモデルを強化しています。この市場は、栄養補助食品、潤滑剤、技術を駆使した治療ソリューションなど、ウェルネス産業によるセクシャルヘルスへの投資によってさらに活性化しており、FSDケアの全体的なエコシステムに貢献しています。

セグメント

医薬品（フリバンセリン、ブレメラノチド、オスペミフェン、エストロゲン療法、その他の医薬品）、疾患（性交疼痛症、性欲減退症、その他の疾患）、投与経路（経口剤、非経口剤、局所剤）、流通チャネル（病院薬局流通チャネル、小売薬局流通チャネル、オンライン薬局流通チャネル）

調査対象企業の例

  • AbbVie Inc.
  • Allergan plc
  • AMAG Pharmaceuticals, Inc.
  • Apricus Biosciences, Inc.
  • Bayer AG
  • Cipla Limited
  • Duchesnay Inc.
  • Emotional Brain BV
  • F. Hoffmann-La Roche Ltd.
  • Freya Pharma Solutions
  • GSK plc（GlaxoSmithKline）
  • Lawley Pharmaceuticals Pty Ltd.
  • Merck & Co., Inc.
  • Millicent Pharma Limited
  • Novo Nordisk A/S
  • Palatin Technologies, Inc.
  • Pfizer Inc.
  • Pivot Pharmaceuticals Inc.
  • Sprout Pharmaceuticals, Inc.
  • TherapeuticsMD, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP30918

Global Female Sexual Dysfunction Treatment Market to Reach US$853.8 Million by 2030

The global market for Female Sexual Dysfunction Treatment estimated at US$528.6 Million in the year 2024, is expected to reach US$853.8 Million by 2030, growing at a CAGR of 8.3% over the analysis period 2024-2030. Flibanserin, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$342.4 Million by the end of the analysis period. Growth in the Bremelanotide segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$144.0 Million While China is Forecast to Grow at 13.0% CAGR

The Female Sexual Dysfunction Treatment market in the U.S. is estimated at US$144.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$184.6 Million by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global Female Sexual Dysfunction Treatment Market - Key Trends & Drivers Summarized

Why Is Female Sexual Dysfunction Finally Receiving Clinical and Commercial Attention?

After decades of limited recognition, female sexual dysfunction (FSD) is now being acknowledged as a significant and multifaceted health issue, spurring focused clinical attention and market development. Affecting an estimated 40-50% of women globally at some point in their lives, FSD encompasses a range of conditions including low libido (hypoactive sexual desire disorder), arousal disorders, orgasmic dysfunction, and pain-related conditions like dyspareunia. Historically underdiagnosed due to societal taboos, stigma, and lack of medical training, this condition is increasingly being seen as a legitimate component of women’s overall health and well-being. The shift is due in part to evolving cultural attitudes, a growing female voice in health advocacy, and increased demand for sexual wellness solutions beyond reproductive health. In response, healthcare providers and pharmaceutical companies are beginning to approach FSD with the same scientific rigor applied to male sexual dysfunction. This includes the development of specific diagnostic criteria, FDA-approved therapies like flibanserin and bremelanotide, and a growing body of clinical research dedicated to understanding hormonal, neurological, psychological, and relational factors underlying FSD.

How Are Pharmaceutical and Non-Pharmaceutical Innovations Changing the Treatment Landscape?

The treatment landscape for FSD is expanding beyond hormone-based solutions to include a wider spectrum of pharmaceutical and non-pharmaceutical options. Traditional therapies such as estrogen replacement or androgen therapy are now being complemented by centrally acting agents like flibanserin, which targets serotonin and dopamine pathways to enhance sexual desire. Bremelanotide, a melanocortin receptor agonist, represents another breakthrough, offering on-demand therapy for premenopausal women. Alongside these, researchers are exploring novel classes of drugs including oxytocin analogs and selective estrogen receptor modulators, with several in various stages of clinical trials. Non-pharmacological approaches are also gaining traction, particularly among women seeking holistic or non-invasive alternatives. These include cognitive-behavioral therapy, mindfulness-based interventions, pelvic floor physiotherapy, and the use of high-tech devices like vaginal lasers and neuromodulation tools. Telemedicine platforms and digital therapeutics are making treatment more accessible, discreet, and customizable, especially for women in underserved or conservative settings. The integration of sexual wellness into broader women’s health apps is further destigmatizing FSD and facilitating symptom tracking, behavior modification, and virtual counseling.

What Cultural, Psychological, and Demographic Shifts Are Driving Treatment Uptake?

Shifts in cultural narratives, psychological awareness, and demographic patterns are collectively driving a higher demand for FSD treatments. Women today are more empowered to prioritize their sexual well-being and communicate openly with healthcare providers, thanks to broader social acceptance and education surrounding female sexuality. Millennials and Gen Z, in particular, are helping redefine sexual health as a quality-of-life issue rather than a taboo topic, while postmenopausal women-often overlooked in the past-are demanding solutions that address age-related changes in libido and comfort. Additionally, rising awareness of mental health’s connection to sexual function has made psychological factors like anxiety, body image, and relationship dynamics part of the diagnostic and treatment process. In parallel, the popularity of wellness culture, body positivity, and sex-positive feminism has propelled a consumer-driven demand for products and services that support sexual fulfillment. As a result, women are increasingly turning to specialized clinics, online platforms, and retail wellness brands for both clinical treatments and lifestyle-enhancing supplements. These attitudinal shifts are creating a more receptive market environment and encouraging more robust discussions between patients and providers.

Which Industry Forces and Clinical Needs Are Accelerating Global Market Growth?

The growth in the Female Sexual Dysfunction Treatment market is driven by several factors rooted in medical advancements, shifting consumer preferences, and the evolution of healthcare delivery systems. Key among them is the increasing number of women seeking medical intervention for sexual wellness, supported by greater awareness, education, and accessibility to women-centric healthcare services. Pharmaceutical companies are actively investing in R&D for targeted therapies, with a growing pipeline of drugs addressing multiple FSD subtypes and hormonal profiles. The expansion of telehealth and direct-to-consumer platforms has drastically improved access to confidential consultations and prescription services, especially in markets where in-person discussions around sexual health remain taboo. Rising healthcare expenditure and insurance coverage in developed countries are also enabling more women to explore both traditional and emerging treatments. In addition, the aging global female population-especially in regions with high life expectancy-is creating sustained demand for postmenopausal sexual health solutions. Cross-sector collaborations between gynecologists, endocrinologists, mental health professionals, and sexual health specialists are enhancing multidisciplinary care models that better address the complex nature of FSD. The market is further energized by the wellness industry’s investment in sexual health, with nutraceuticals, lubricants, and tech-enabled therapy solutions contributing to a holistic ecosystem of FSD care.

SCOPE OF STUDY:

The report analyzes the Female Sexual Dysfunction Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy, Other Drugs); Disease (Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease, Other Diseases); Route of Administration (Oral, Parenteral, Topical); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Allergan plc
  • AMAG Pharmaceuticals, Inc.
  • Apricus Biosciences, Inc.
  • Bayer AG
  • Cipla Limited
  • Duchesnay Inc.
  • Emotional Brain BV
  • F. Hoffmann-La Roche Ltd.
  • Freya Pharma Solutions
  • GSK plc (GlaxoSmithKline)
  • Lawley Pharmaceuticals Pty Ltd.
  • Merck & Co., Inc.
  • Millicent Pharma Limited
  • Novo Nordisk A/S
  • Palatin Technologies, Inc.
  • Pfizer Inc.
  • Pivot Pharmaceuticals Inc.
  • Sprout Pharmaceuticals, Inc.
  • TherapeuticsMD, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Female Sexual Dysfunction Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Public Discourse Around Women's Sexual Health Throws the Spotlight on Female Sexual Dysfunction Treatment
    • Rising Awareness and Diagnosis Rates Spur Demand for Evidence-Based Therapeutic Options
    • Underaddressed Psychological Components of Sexual Dysfunction Strengthen the Business Case for Holistic Treatment Models
    • Pharmaceutical Innovation and New Drug Approvals Propel Growth of Targeted Therapies for Female Sexual Dysfunction
    • Expanding Interest in Hormonal and Non-Hormonal Therapies Broadens the Addressable Treatment Market
    • Increasing Influence of Digital Health Platforms Drives Adoption of App-Based and Virtual Care Solutions
    • Delayed Childbearing and Menopause Trends Generate Demand for Long-Term Sexual Health Interventions
    • Social Stigma and Limited Patient-Physician Dialogue Create Challenges but Also Fuel Demand for Discreet Treatment Channels
    • Clinical Research Advancements in Sexual Function Biology Accelerate Development of Novel Mechanisms of Action
    • Integration of Sexual Wellness into Broader Women's Health Portfolios Sustains Growth Across Therapeutic Categories
    • Consumer-Driven Demand for Non-Invasive and Natural Therapies Spurs Innovation in OTC and Supplement-Based Products
    • Growing Medicalization of Female Sexual Health Expands Physician Engagement and Screening Practices
    • Cultural Shifts in Emerging Markets Generate Opportunities for Market Expansion and Education Campaigns
    • Mental Health Awareness Movement Drives Cross-Disciplinary Approaches to Treatment of Sexual Dysfunction
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Female Sexual Dysfunction Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Female Sexual Dysfunction Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Female Sexual Dysfunction Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Flibanserin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Flibanserin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Flibanserin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Bremelanotide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Bremelanotide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Bremelanotide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Ospemifene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Ospemifene by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Ospemifene by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Estrogen Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Estrogen Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Estrogen Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Online Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Dyspareunia Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Dyspareunia Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Dyspareunia Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Hypoactive Sexual Desire Disorder Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Hypoactive Sexual Desire Disorder Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Hypoactive Sexual Desire Disorder Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Female Sexual Dysfunction Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • JAPAN
    • Female Sexual Dysfunction Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • CHINA
    • Female Sexual Dysfunction Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • EUROPE
    • Female Sexual Dysfunction Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Female Sexual Dysfunction Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Female Sexual Dysfunction Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • FRANCE
    • Female Sexual Dysfunction Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 110: France Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • GERMANY
    • Female Sexual Dysfunction Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Female Sexual Dysfunction Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 146: UK Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: UK 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Spain 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Spain 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Spain 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Russia 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Russia 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Russia 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Europe 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Female Sexual Dysfunction Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Female Sexual Dysfunction Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Female Sexual Dysfunction Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Female Sexual Dysfunction Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Australia 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Australia 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Australia 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • INDIA
    • Female Sexual Dysfunction Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 221: India Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: India 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: India 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 230: India Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: India Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: India 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: South Korea 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: South Korea 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: South Korea 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Female Sexual Dysfunction Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Female Sexual Dysfunction Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Female Sexual Dysfunction Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Latin America 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Latin America 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Latin America 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Argentina 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Argentina 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Argentina 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Brazil 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Brazil 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Brazil Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Brazil 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Mexico 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Mexico 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Mexico Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Mexico 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Rest of Latin America 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Female Sexual Dysfunction Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Female Sexual Dysfunction Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Female Sexual Dysfunction Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 328: Middle East 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 331: Middle East 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 334: Middle East 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 340: Iran 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 343: Iran 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 344: Iran Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Iran Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 346: Iran 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 352: Israel 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 355: Israel 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 356: Israel Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Israel Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 358: Israel 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 370: Saudi Arabia 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 376: UAE 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 379: UAE 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 380: UAE Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: UAE Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 382: UAE 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 394: Rest of Middle East 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030
  • AFRICA
    • Female Sexual Dysfunction Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Female Sexual Dysfunction Treatment by Drug - Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Female Sexual Dysfunction Treatment by Drug - Percentage Breakdown of Value Sales for Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy and Other Drugs for the Years 2015, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Female Sexual Dysfunction Treatment by Route Of Administration - Parenteral, Topical and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 400: Africa 15-Year Perspective for Female Sexual Dysfunction Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Topical and Oral for the Years 2015, 2025 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Female Sexual Dysfunction Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 403: Africa 15-Year Perspective for Female Sexual Dysfunction Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
    • TABLE 404: Africa Recent Past, Current & Future Analysis for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Africa Historic Review for Female Sexual Dysfunction Treatment by Disease - Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 406: Africa 15-Year Perspective for Female Sexual Dysfunction Treatment by Disease - Percentage Breakdown of Value Sales for Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease and Other Diseases for the Years 2015, 2025 & 2030

IV. COMPETITION